Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 2—February 2011


Hepatitis E Virus and Neurologic Disorders

Nassim KamarComments to Author , Richard P. Bendall, Jean Marie Peron, Pascal Cintas, Laurent Prudhomme, Jean Michel Mansuy, Lionel Rostaing, Frances Keane, Samreen Ijaz, Jacques Izopet, and Harry R. Dalton
Author affiliations: Author affiliations: Centre Hospitalier Universitaire Rangueil, Toulouse, France (N. Kamar, P. Cintas, L. Rostaing); Université Paul Sabatier, Toulouse (N. Kamar, J.M. Peron, L. Rostaing, J. Izopet); Royal Cornwall Hospital Trust, Truro, UK (R.P. Bendall, F. Keane, H.R. Dalton); Centre Hospitalier Universitaire Purpan, Toulouse (J.M. Peron, J.M. Mansuy, J. Izopet); Centre Hospitalier de Castres, Castres, France (L. Prudhomme); Health Protection Agency, London, UK (S. Ijaz); Peninsula College of Medicine and Dentistry, Truro (H.R. Dalton)

Main Article

Table 2

Clinical presentation for 7 patients with HEV–associated neurologic disorders, Cornwall, UK, and Toulouse, France*

Patient no. Neurologic signs and symptoms Therapy Outcome
1 Acute inflammatory polyradiculoneuropathy Complete resolution
2 Bilateral brachial neuritis Resolution with residual weakness
3 Guillain-Barré syndrome IV Ig Resolution at HEV clearance
4 Ataxia, severe proximal weakness of lower limbs, urine retention, and cognitive dysfunction IS modification Resolution with residual motor deficit
5 Encephalitis IS cessation, foscavir, IV Ig Complete resolution
6 Peripheral demyelinating polyradiculoneuropathy IS modification, IV Ig No improvement
7 Painful sensory peripheral neuropathy Peg-IFN/ribavirin Complete resolution

*HEV, hepatitis E virus; –, no specific therapy; IV Ig, intravenous immunoglobulins; IS, immunosuppressant, Peg-IFN, pegylated interferon.

Main Article